Ilyang Pharm’s ‘Prion Treatment Development’ selection as study supported by MOHW
The Ilyang Pharm’s(CEO Dong-Yeon Kim) development of prion treatment has recently been selected as the ‘Development of Technology to Overcome Diseases Transmitted Cross-species to Humans’ by the Ministry of Health and Welfare(MOHW).
Ilyang Pharm has conducted a broad-scale research with the most...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
